Cargando…

Evaluating the efficacy of upadacitinib in patients with moderate rheumatoid arthritis: a post-hoc analysis of the SELECT phase 3 trials

OBJECTIVES: Moderately active RA is associated with poor patient outcomes. Despite this, some health systems have restricted access to advanced therapies to those with severe RA. There is also limited evidence of the efficacy of advanced therapies in the moderately active RA population. This post-ho...

Descripción completa

Detalles Bibliográficos
Autores principales:	Conaghan, Philip G, Pavelka, Karel, Hsieh, Song-Chou, Bonnington, Terri-Leigh, Kent, Toby C, Marchbank, Katie, Edwards, Christopher J
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2023
Materias:	Concise Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9924096/ https://www.ncbi.nlm.nih.gov/pubmed/36794283 http://dx.doi.org/10.1093/rap/rkad017

Ejemplares similares

Benefit–Risk Analysis of Upadacitinib Compared with Adalimumab in the Treatment of Patients with Moderate-to-Severe Rheumatoid Arthritis
por: Conaghan, Philip, et al.
Publicado: (2021)

Upadacitinib for rheumatoid arthritis
Publicado: (2020)

The role of upadacitinib in the treatment of moderate-to-severe active rheumatoid arthritis
por: Avci, Ali Berkant, et al.
Publicado: (2021)

A Matching-Adjusted Indirect Comparison of Upadacitinib Versus Tofacitinib in Adults with Moderate-to-Severe Rheumatoid Arthritis
por: Edwards, Christopher J., et al.
Publicado: (2020)

Upadacitinib in Rheumatoid Arthritis: A Benefit–Risk Assessment Across a Phase III Program
por: Conaghan, Philip G., et al.
Publicado: (2021)

The Safety Profile of Upadacitinib in Patients with Rheumatoid Arthritis in Japan
por: Yamaoka, Kunihiro, et al.
Publicado: (2021)

Lymphomatoid papulosis during upadacitinib treatment for rheumatoid arthritis
por: Iinuma, Shin, et al.
Publicado: (2022)

Upadacitinib for Patients with Rheumatoid Arthritis: A Comprehensive Review
por: Sanmartí, Raimon, et al.
Publicado: (2023)

Erratum in: Cost per responder for upadacitinib vs abatacept in patients with moderate-to-severe Rheumatoid Arthritis in Italy
por: Caporali, Roberto, et al.
Publicado: (2022)

Kaposi sarcoma in a patient treated with upadacitinib for rheumatoid arthritis
por: Fournier, Cynthia, et al.
Publicado: (2023)

The treatment of Merkel cell carcinoma with immune checkpoint inhibitors: implications for patients with rheumatoid arthritis
por: Klee, Gina, et al.
Publicado: (2021)

Reduced cognitive ability in people with rheumatoid arthritis compared with age-matched healthy controls
por: Gwinnutt, James M, et al.
Publicado: (2021)

Clinical Pharmacokinetics of Upadacitinib: Review of Data Relevant to the Rheumatoid Arthritis Indication
por: Mohamed, Mohamed-Eslam F., et al.
Publicado: (2019)

Impact of initial therapy with upadacitinib or adalimumab on achievement of 48-week treatment goals in patients with rheumatoid arthritis: post hoc analysis of SELECT-COMPARE
por: Mysler, Eduardo, et al.
Publicado: (2022)

Safety profile of upadacitinib in patients at risk of cardiovascular disease: integrated post hoc analysis of the SELECT phase III rheumatoid arthritis clinical programme
por: Fleischmann, Roy, et al.
Publicado: (2023)

Cellular and Molecular Targets of Extracellular Vesicles from Mesenchymal Stem/Stromal Cells in Rheumatoid Arthritis
por: Alcaraz, María José, et al.
Publicado: (2022)

Time to Include Fine Specificity Anti‐Citrullinated Protein Antibodies in the Routine Diagnosis and Management of Rheumatoid Arthritis?
por: Schwenzer, Anja, et al.
Publicado: (2019)

Extra-articular findings with FDG-PET/CT in rheumatoid arthritis patients: more harm than benefit
por: Ulijn, Evy, et al.
Publicado: (2022)

Upadacitinib for the treatment of psoriatic arthritis
por: Fonseca, Diogo, et al.
Publicado: (2023)

Burden of rheumatoid arthritis among US Medicare population: co-morbidities, health-care resource utilization and costs
por: Chen, Chieh-I, et al.
Publicado: (2018)

Rheumatoid arthritis patients with predominantly tender joints rarely achieve clinical remission despite being in ultrasound remission
por: Hammer, Hilde Berner, et al.
Publicado: (2021)

Mindfulness-based stress reduction to improve depression, pain and high patient global assessment in controlled rheumatoid arthritis
por: Gaboury, Isabelle, et al.
Publicado: (2022)

Upadacitinib and filgotinib: the role of JAK1 selective inhibition in the treatment of rheumatoid arthritis
por: Biggioggero, Martina, et al.
Publicado: (2019)

Primary care challenges in diagnosing and referring patients with suspected rheumatoid arthritis: a national cross-sectional GP survey
por: Scott, Ian C, et al.
Publicado: (2018)

Impact of the COVID-19 pandemic on patients with rheumatoid arthritis: data from the Ontario Best Practices Research Initiative (OBRI)
por: Wong-Pack, Matthew, et al.
Publicado: (2023)

Use of rheumatoid arthritis impact of disease (RAID) in routine care; identification of DAS28 remission and unmet patient-reported outcomes
por: Mistry, Jatin, et al.
Publicado: (2020)

Sarilumab reduces disease activity in rheumatoid arthritis patients with inadequate response to janus kinase inhibitors or tocilizumab in regular care in Germany
por: Tony, Hans-Peter, et al.
Publicado: (2022)

Incidence of Disease Flare After BNT162b2 Coronavirus Disease 2019 Vaccination in Patients With Rheumatoid Arthritis in Remission
por: Bixio, Riccardo, et al.
Publicado: (2021)

Should quantitative assessment of rheumatoid arthritis include measures of joint damage and patient distress, in addition to measures of apparent inflammatory activity?
por: Pincus, Theodore, et al.
Publicado: (2022)

Rituximab, but not other biologics, impairs humoral immunity in patients with rheumatoid arthritis—a study using CoVariant protein arrays
por: Lin, Wei-Hsun, et al.
Publicado: (2023)

MACE and VTE across upadacitinib clinical trial programmes in rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis
por: Charles-Schoeman, Christina, et al.
Publicado: (2023)

Janus Kinase Inhibitors in Rheumatoid Arthritis: An Update on the Efficacy and Safety of Tofacitinib, Baricitinib and Upadacitinib
por: Harrington, Robert, et al.
Publicado: (2023)

Beyond the visual analog scale: results from a multimodal pain assessment pilot study in first‐degree relatives of patients with rheumatoid arthritis
por: McDougall, Cairistin, et al.
Publicado: (2022)

Effect of upadacitinib on reducing pain in patients with active psoriatic arthritis or ankylosing spondylitis: post hoc analysis of three randomised clinical trials
por: McInnes, Iain B, et al.
Publicado: (2022)

Efficacy and safety of upadacitinib over 84 weeks in Japanese patients with rheumatoid arthritis (SELECT-SUNRISE)
por: Kameda, Hideto, et al.
Publicado: (2021)

Predicting disease progression and poor outcomes in patients with moderately active rheumatoid arthritis: a systematic review
por: Edwards, Christopher J, et al.
Publicado: (2019)

Upadacitinib versus placebo or adalimumab with background methotrexate in patients with rheumatoid arthritis and an inadequate response to methotrexate: a subgroup analysis of a phase III randomized controlled trial in Central and Eastern European patients
por: Pavelka, Karel, et al.
Publicado: (2020)

Safety profile of upadacitinib over 15 000 patient-years across rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and atopic dermatitis
por: Burmester, Gerd R, et al.
Publicado: (2023)

Pharmacokinetics of Upadacitinib With the Clinical Regimens of the Extended‐Release Formulation Utilized in Rheumatoid Arthritis Phase 3 Trials
por: Mohamed, Mohamed‐Eslam F., et al.
Publicado: (2018)

Safety profile of upadacitinib in rheumatoid arthritis: integrated analysis from the SELECT phase III clinical programme
por: Cohen, Stanley B, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_19rsrbi7ng41j87r8j0oalg0lr